Engitix Therapeutics appoints Dr Mike Burbridge as VP Oncology and Immuno-oncology
Engitix Ltd (‘Engitix’), a biotechnology company developing a portfolio of programmes in fibrosis and solid tumours and with two significant partnerships based on its pioneering proprietary human extracellular matrix (ECM) drug discovery platform, today announced that it has appointed Dr Mike Burbridge, as Vice President, Oncology & Immuno-oncology. Dr Gino Van Heeke, Engitix’s CSO said “We are delighted to have attracted a scientist as high calibre as Mike, who has the experience and expertise to help push forward our internal therapeutic projects as well as our partnered programmes...
Source: biospace.com